PolyPeptide Shareholders Overwhelmingly Approve All AGM Proposals

PolyPeptide Group AG (SIX: PPGN), a specialized global Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients, has successfully concluded its fifth annual General Meeting (AGM 2026) with overwhelming shareholder approval. The meeting, held at the Chollerhalle in Zug, Switzerland, saw 80.85% of issued registered shares represented, demonstrating strong investor engagement. Shareholders approved all proposals from the Board of Directors, including the re-election of all six board members, with Peter Wilden confirmed as Chair and both Wilden and Philippe Weber re-elected to the Remuneration and Nomination Committee. Other approved measures included the re-election of Statutory Auditors and Independent Proxy, approval of compensation limits for the Board and Executive Committee, and formal acceptance of the 2025 financial reports and Remuneration Report. The minutes of this significant corporate governance event will be available on the company's website within 15 days, with the next AGM scheduled for April 7, 2027.

The company, which operates six GMP-certified facilities across Europe, the U.S., and India, plays a crucial role in the pharmaceutical supply chain by developing and manufacturing peptide-based APIs that support treatments for metabolic diseases, including GLP-1 therapies. This shareholder endorsement comes at a pivotal time for PolyPeptide as it capitalizes on growing demand in the peptide therapeutics market. The approved proposals ensure leadership continuity and governance stability, which are essential for navigating the complex regulatory landscape of pharmaceutical manufacturing. Investors and stakeholders can find additional information through the company's corporate communications and investor relations contacts, or by visiting polypeptide.com for comprehensive details about their operations and future directions.

This development reinforces PolyPeptide's position as a key player in the global CDMO sector, particularly in the high-growth area of peptide-based medicines. The shareholder support reflects confidence in the company's strategic direction and management team, which is critical for maintaining partnerships with pharmaceutical and biotech clients. As the industry faces increasing pressure to deliver innovative treatments, PolyPeptide's specialized expertise and robust manufacturing capabilities position it to contribute significantly to patient health worldwide. For those following the company's progress, this AGM outcome signals continued stability and growth potential, with all relevant documents and updates accessible through their official channels and platforms like LinkedIn.